# Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma

> **NCT07312578** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Peking University** · enrollment: 48 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nimotuzumab
- **DRUG:** camrelizumab
- **DRUG:** Albumin paclitaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT07312578
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-11-01
- **Primary completion:** 2027-11-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07312578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07312578, "Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07312578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*